nodes	percent_of_prediction	percent_of_DWPC	metapath
Ketorolac—PTGS2—urinary bladder cancer	0.512	1	CbGaD
Ketorolac—PTGS2—Cisplatin—urinary bladder cancer	0.0852	0.356	CbGbCtD
Ketorolac—PTGS2—Etoposide—urinary bladder cancer	0.0837	0.349	CbGbCtD
Ketorolac—PTGS1—Etoposide—urinary bladder cancer	0.0707	0.295	CbGbCtD
Ketorolac—Suprofen—UGT2B7—urinary bladder cancer	0.00196	0.282	CrCbGaD
Ketorolac—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—urinary bladder cancer	0.00134	0.0505	CbGpPWpGaD
Ketorolac—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—urinary bladder cancer	0.00124	0.0467	CbGpPWpGaD
Ketorolac—Tolmetin—CXCL8—urinary bladder cancer	0.00116	0.166	CrCbGaD
Ketorolac—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—urinary bladder cancer	0.00106	0.0401	CbGpPWpGaD
Ketorolac—PTGS1—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000911	0.0343	CbGpPWpGaD
Ketorolac—Tolmetin—MPO—urinary bladder cancer	0.000901	0.129	CrCbGaD
Ketorolac—PTGS2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000723	0.0272	CbGpPWpGaD
Ketorolac—PTGS1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000638	0.024	CbGpPWpGaD
Ketorolac—PTGS2—C-MYB transcription factor network—PTCRA—urinary bladder cancer	0.00058	0.0218	CbGpPWpGaD
Ketorolac—Ketoprofen—CXCL8—urinary bladder cancer	0.000565	0.081	CrCbGaD
Ketorolac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—GSTO2—urinary bladder cancer	0.000564	0.0212	CbGpPWpGaD
Ketorolac—PTGS1—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000484	0.0183	CbGpPWpGaD
Ketorolac—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—urinary bladder cancer	0.000467	0.0176	CbGpPWpGaD
Ketorolac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC19A1—urinary bladder cancer	0.000438	0.0165	CbGpPWpGaD
Ketorolac—PTGS1—Biological oxidations—GSTZ1—urinary bladder cancer	0.000434	0.0164	CbGpPWpGaD
Ketorolac—Tiaprofenic acid—PTGS2—urinary bladder cancer	0.000427	0.0612	CrCbGaD
Ketorolac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—PRSS3—urinary bladder cancer	0.000427	0.0161	CbGpPWpGaD
Ketorolac—PTGS1—Biological oxidations—GSTO2—urinary bladder cancer	0.000412	0.0155	CbGpPWpGaD
Ketorolac—PTGS1—Biological oxidations—NAT1—urinary bladder cancer	0.000412	0.0155	CbGpPWpGaD
Ketorolac—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000411	0.0155	CbGpPWpGaD
Ketorolac—Nepafenac—PTGS2—urinary bladder cancer	0.000406	0.0583	CrCbGaD
Ketorolac—Fenbufen—PTGS2—urinary bladder cancer	0.000389	0.0557	CrCbGaD
Ketorolac—PTGS2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000385	0.0145	CbGpPWpGaD
Ketorolac—PTGS1—Biological oxidations—UGT2B7—urinary bladder cancer	0.000376	0.0142	CbGpPWpGaD
Ketorolac—PTGS1—Overview of nanoparticle effects—PTGS2—urinary bladder cancer	0.000366	0.0138	CbGpPWpGaD
Ketorolac—PTGS1—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	0.000355	0.0134	CbGpPWpGaD
Ketorolac—PTGS1—Biological oxidations—CYP4B1—urinary bladder cancer	0.000339	0.0128	CbGpPWpGaD
Ketorolac—Tolmetin—PTGS2—urinary bladder cancer	0.000338	0.0484	CrCbGaD
Ketorolac—Salsalate—PTGS2—urinary bladder cancer	0.000338	0.0484	CrCbGaD
Ketorolac—PTGS2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000331	0.0125	CbGpPWpGaD
Ketorolac—Suprofen—PTGS2—urinary bladder cancer	0.000324	0.0464	CrCbGaD
Ketorolac—PTGS2—S1P1 pathway—RHOA—urinary bladder cancer	0.000321	0.0121	CbGpPWpGaD
Ketorolac—PTGS1—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000304	0.0115	CbGpPWpGaD
Ketorolac—PTGS1—Eicosanoid Synthesis—PTGS2—urinary bladder cancer	0.000303	0.0114	CbGpPWpGaD
Ketorolac—PTGS2—C-MYB transcription factor network—BIRC3—urinary bladder cancer	0.000293	0.011	CbGpPWpGaD
Ketorolac—PTGS1—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000287	0.0108	CbGpPWpGaD
Ketorolac—PTGS2—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	0.000282	0.0106	CbGpPWpGaD
Ketorolac—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000254	0.00957	CbGpPWpGaD
Ketorolac—PTGS2—C-MYB transcription factor network—MPO—urinary bladder cancer	0.000251	0.00945	CbGpPWpGaD
Ketorolac—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—urinary bladder cancer	0.000248	0.00935	CbGpPWpGaD
Ketorolac—PTGS1—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000247	0.00931	CbGpPWpGaD
Ketorolac—PTGS2—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000242	0.0091	CbGpPWpGaD
Ketorolac—PTGS2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000227	0.00857	CbGpPWpGaD
Ketorolac—PTGS1—Biological oxidations—NAT2—urinary bladder cancer	0.000225	0.0085	CbGpPWpGaD
Ketorolac—PTGS2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000199	0.00752	CbGpPWpGaD
Ketorolac—PTGS2—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000196	0.00739	CbGpPWpGaD
Ketorolac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—urinary bladder cancer	0.000192	0.00723	CbGpPWpGaD
Ketorolac—PTGS1—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000191	0.0072	CbGpPWpGaD
Ketorolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—urinary bladder cancer	0.000187	0.00706	CbGpPWpGaD
Ketorolac—PTGS1—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000182	0.00687	CbGpPWpGaD
Ketorolac—PTGS1—Biological oxidations—HPGDS—urinary bladder cancer	0.00018	0.00679	CbGpPWpGaD
Ketorolac—PTGS1—Biological oxidations—GSTT1—urinary bladder cancer	0.000175	0.00659	CbGpPWpGaD
Ketorolac—PTGS2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000174	0.00656	CbGpPWpGaD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000173	0.0065	CbGpPWpGaD
Ketorolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—urinary bladder cancer	0.00017	0.00641	CbGpPWpGaD
Ketorolac—PTGS1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000169	0.00636	CbGpPWpGaD
Ketorolac—PTGS1—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000168	0.00634	CbGpPWpGaD
Ketorolac—Ketoprofen—PTGS2—urinary bladder cancer	0.000165	0.0236	CrCbGaD
Ketorolac—PTGS2—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.000157	0.00591	CbGpPWpGaD
Ketorolac—PTGS2—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.000157	0.00591	CbGpPWpGaD
Ketorolac—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000152	0.00572	CbGpPWpGaD
Ketorolac—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000145	0.00545	CbGpPWpGaD
Ketorolac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000135	0.00508	CbGpPWpGaD
Ketorolac—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000134	0.00503	CbGpPWpGaD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000132	0.00496	CbGpPWpGaD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000131	0.00493	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00013	0.0049	CbGpPWpGaD
Ketorolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	0.00013	0.00489	CbGpPWpGaD
Ketorolac—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000125	0.00472	CbGpPWpGaD
Ketorolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	0.000124	0.00468	CbGpPWpGaD
Ketorolac—PTGS1—prostate gland—urinary bladder cancer	0.000123	0.0904	CbGeAlD
Ketorolac—PTGS1—Biological oxidations—GSTP1—urinary bladder cancer	0.000121	0.00457	CbGpPWpGaD
Ketorolac—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000119	0.00449	CbGpPWpGaD
Ketorolac—PTGS2—prostate gland—urinary bladder cancer	0.000118	0.0864	CbGeAlD
Ketorolac—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000116	0.00436	CbGpPWpGaD
Ketorolac—PTGS1—Biological oxidations—GSTM1—urinary bladder cancer	0.000111	0.0042	CbGpPWpGaD
Ketorolac—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	0.000108	0.00407	CbGpPWpGaD
Ketorolac—PTGS1—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000107	0.00404	CbGpPWpGaD
Ketorolac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	0.000106	0.004	CbGpPWpGaD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000105	0.00397	CbGpPWpGaD
Ketorolac—PTGS1—seminal vesicle—urinary bladder cancer	0.000104	0.0765	CbGeAlD
Ketorolac—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000104	0.00391	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000103	0.00389	CbGpPWpGaD
Ketorolac—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000101	0.00382	CbGpPWpGaD
Ketorolac—PTGS2—seminal vesicle—urinary bladder cancer	9.98e-05	0.0731	CbGeAlD
Ketorolac—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	9.66e-05	0.00364	CbGpPWpGaD
Ketorolac—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	9.59e-05	0.00361	CbGpPWpGaD
Ketorolac—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	9.46e-05	0.00356	CbGpPWpGaD
Ketorolac—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	9.43e-05	0.00355	CbGpPWpGaD
Ketorolac—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	9.18e-05	0.000429	CcSEcCtD
Ketorolac—Epistaxis—Doxorubicin—urinary bladder cancer	9.15e-05	0.000428	CcSEcCtD
Ketorolac—Angiopathy—Methotrexate—urinary bladder cancer	9.13e-05	0.000427	CcSEcCtD
Ketorolac—Immune system disorder—Methotrexate—urinary bladder cancer	9.09e-05	0.000425	CcSEcCtD
Ketorolac—Dizziness—Fluorouracil—urinary bladder cancer	9.09e-05	0.000425	CcSEcCtD
Ketorolac—Visual impairment—Epirubicin—urinary bladder cancer	9.07e-05	0.000424	CcSEcCtD
Ketorolac—PTGS1—epithelium—urinary bladder cancer	9.07e-05	0.0664	CbGeAlD
Ketorolac—Mediastinal disorder—Methotrexate—urinary bladder cancer	9.07e-05	0.000424	CcSEcCtD
Ketorolac—Agranulocytosis—Doxorubicin—urinary bladder cancer	9.06e-05	0.000424	CcSEcCtD
Ketorolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	9.04e-05	0.00341	CbGpPWpGaD
Ketorolac—Chills—Methotrexate—urinary bladder cancer	9.03e-05	0.000422	CcSEcCtD
Ketorolac—Diarrhoea—Cisplatin—urinary bladder cancer	8.91e-05	0.000417	CcSEcCtD
Ketorolac—Erythema multiforme—Epirubicin—urinary bladder cancer	8.9e-05	0.000416	CcSEcCtD
Ketorolac—Alopecia—Methotrexate—urinary bladder cancer	8.89e-05	0.000416	CcSEcCtD
Ketorolac—Vomiting—Gemcitabine—urinary bladder cancer	8.89e-05	0.000416	CcSEcCtD
Ketorolac—Bradycardia—Doxorubicin—urinary bladder cancer	8.87e-05	0.000415	CcSEcCtD
Ketorolac—Mental disorder—Methotrexate—urinary bladder cancer	8.82e-05	0.000412	CcSEcCtD
Ketorolac—Rash—Gemcitabine—urinary bladder cancer	8.81e-05	0.000412	CcSEcCtD
Ketorolac—Dermatitis—Gemcitabine—urinary bladder cancer	8.8e-05	0.000412	CcSEcCtD
Ketorolac—Eye disorder—Epirubicin—urinary bladder cancer	8.8e-05	0.000412	CcSEcCtD
Ketorolac—Hypersensitivity—Etoposide—urinary bladder cancer	8.79e-05	0.000411	CcSEcCtD
Ketorolac—Tinnitus—Epirubicin—urinary bladder cancer	8.78e-05	0.000411	CcSEcCtD
Ketorolac—Erythema—Methotrexate—urinary bladder cancer	8.76e-05	0.00041	CcSEcCtD
Ketorolac—Malnutrition—Methotrexate—urinary bladder cancer	8.76e-05	0.00041	CcSEcCtD
Ketorolac—Haemoglobin—Doxorubicin—urinary bladder cancer	8.76e-05	0.00041	CcSEcCtD
Ketorolac—Headache—Gemcitabine—urinary bladder cancer	8.76e-05	0.00041	CcSEcCtD
Ketorolac—PTGS1—smooth muscle tissue—urinary bladder cancer	8.74e-05	0.064	CbGeAlD
Ketorolac—Cardiac disorder—Epirubicin—urinary bladder cancer	8.74e-05	0.000409	CcSEcCtD
Ketorolac—Flushing—Epirubicin—urinary bladder cancer	8.74e-05	0.000409	CcSEcCtD
Ketorolac—Vomiting—Fluorouracil—urinary bladder cancer	8.74e-05	0.000409	CcSEcCtD
Ketorolac—Rhinitis—Doxorubicin—urinary bladder cancer	8.73e-05	0.000409	CcSEcCtD
Ketorolac—Haemorrhage—Doxorubicin—urinary bladder cancer	8.71e-05	0.000408	CcSEcCtD
Ketorolac—Hepatitis—Doxorubicin—urinary bladder cancer	8.71e-05	0.000408	CcSEcCtD
Ketorolac—PTGS2—epithelium—urinary bladder cancer	8.67e-05	0.0635	CbGeAlD
Ketorolac—Rash—Fluorouracil—urinary bladder cancer	8.66e-05	0.000405	CcSEcCtD
Ketorolac—Dermatitis—Fluorouracil—urinary bladder cancer	8.66e-05	0.000405	CcSEcCtD
Ketorolac—Headache—Fluorouracil—urinary bladder cancer	8.61e-05	0.000403	CcSEcCtD
Ketorolac—Urinary tract disorder—Doxorubicin—urinary bladder cancer	8.6e-05	0.000403	CcSEcCtD
Ketorolac—Dysgeusia—Methotrexate—urinary bladder cancer	8.58e-05	0.000401	CcSEcCtD
Ketorolac—Asthenia—Etoposide—urinary bladder cancer	8.56e-05	0.000401	CcSEcCtD
Ketorolac—Connective tissue disorder—Doxorubicin—urinary bladder cancer	8.56e-05	0.000401	CcSEcCtD
Ketorolac—Angiopathy—Epirubicin—urinary bladder cancer	8.54e-05	0.0004	CcSEcCtD
Ketorolac—Urethral disorder—Doxorubicin—urinary bladder cancer	8.54e-05	0.0004	CcSEcCtD
Ketorolac—Immune system disorder—Epirubicin—urinary bladder cancer	8.51e-05	0.000398	CcSEcCtD
Ketorolac—Mediastinal disorder—Epirubicin—urinary bladder cancer	8.49e-05	0.000397	CcSEcCtD
Ketorolac—Back pain—Methotrexate—urinary bladder cancer	8.47e-05	0.000396	CcSEcCtD
Ketorolac—Chills—Epirubicin—urinary bladder cancer	8.45e-05	0.000395	CcSEcCtD
Ketorolac—Pruritus—Etoposide—urinary bladder cancer	8.44e-05	0.000395	CcSEcCtD
Ketorolac—PTGS1—renal system—urinary bladder cancer	8.42e-05	0.0616	CbGeAlD
Ketorolac—Arrhythmia—Epirubicin—urinary bladder cancer	8.41e-05	0.000394	CcSEcCtD
Ketorolac—Visual impairment—Doxorubicin—urinary bladder cancer	8.4e-05	0.000393	CcSEcCtD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	8.37e-05	0.00316	CbGpPWpGaD
Ketorolac—PTGS2—smooth muscle tissue—urinary bladder cancer	8.36e-05	0.0612	CbGeAlD
Ketorolac—Alopecia—Epirubicin—urinary bladder cancer	8.32e-05	0.000389	CcSEcCtD
Ketorolac—Nausea—Gemcitabine—urinary bladder cancer	8.3e-05	0.000388	CcSEcCtD
Ketorolac—Vomiting—Cisplatin—urinary bladder cancer	8.28e-05	0.000387	CcSEcCtD
Ketorolac—Vision blurred—Methotrexate—urinary bladder cancer	8.25e-05	0.000386	CcSEcCtD
Ketorolac—Mental disorder—Epirubicin—urinary bladder cancer	8.25e-05	0.000386	CcSEcCtD
Ketorolac—Erythema multiforme—Doxorubicin—urinary bladder cancer	8.24e-05	0.000385	CcSEcCtD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	8.23e-05	0.0031	CbGpPWpGaD
Ketorolac—Rash—Cisplatin—urinary bladder cancer	8.21e-05	0.000384	CcSEcCtD
Ketorolac—Dermatitis—Cisplatin—urinary bladder cancer	8.21e-05	0.000384	CcSEcCtD
Ketorolac—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	8.2e-05	0.00309	CbGpPWpGaD
Ketorolac—Malnutrition—Epirubicin—urinary bladder cancer	8.2e-05	0.000383	CcSEcCtD
Ketorolac—Erythema—Epirubicin—urinary bladder cancer	8.2e-05	0.000383	CcSEcCtD
Ketorolac—Diarrhoea—Etoposide—urinary bladder cancer	8.17e-05	0.000382	CcSEcCtD
Ketorolac—Nausea—Fluorouracil—urinary bladder cancer	8.16e-05	0.000382	CcSEcCtD
Ketorolac—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	8.15e-05	0.00307	CbGpPWpGaD
Ketorolac—Eye disorder—Doxorubicin—urinary bladder cancer	8.14e-05	0.000381	CcSEcCtD
Ketorolac—Ill-defined disorder—Methotrexate—urinary bladder cancer	8.13e-05	0.00038	CcSEcCtD
Ketorolac—Tinnitus—Doxorubicin—urinary bladder cancer	8.12e-05	0.00038	CcSEcCtD
Ketorolac—Anaemia—Methotrexate—urinary bladder cancer	8.1e-05	0.000379	CcSEcCtD
Ketorolac—Flushing—Doxorubicin—urinary bladder cancer	8.09e-05	0.000378	CcSEcCtD
Ketorolac—Cardiac disorder—Doxorubicin—urinary bladder cancer	8.09e-05	0.000378	CcSEcCtD
Ketorolac—Flatulence—Epirubicin—urinary bladder cancer	8.08e-05	0.000378	CcSEcCtD
Ketorolac—PTGS2—renal system—urinary bladder cancer	8.05e-05	0.0589	CbGeAlD
Ketorolac—Tension—Epirubicin—urinary bladder cancer	8.04e-05	0.000376	CcSEcCtD
Ketorolac—Dysgeusia—Epirubicin—urinary bladder cancer	8.03e-05	0.000376	CcSEcCtD
Ketorolac—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	7.99e-05	0.00301	CbGpPWpGaD
Ketorolac—Nervousness—Epirubicin—urinary bladder cancer	7.96e-05	0.000372	CcSEcCtD
Ketorolac—Back pain—Epirubicin—urinary bladder cancer	7.93e-05	0.000371	CcSEcCtD
Ketorolac—Angiopathy—Doxorubicin—urinary bladder cancer	7.9e-05	0.00037	CcSEcCtD
Ketorolac—PTGS2—urethra—urinary bladder cancer	7.9e-05	0.0578	CbGeAlD
Ketorolac—Malaise—Methotrexate—urinary bladder cancer	7.9e-05	0.00037	CcSEcCtD
Ketorolac—Dizziness—Etoposide—urinary bladder cancer	7.89e-05	0.000369	CcSEcCtD
Ketorolac—Immune system disorder—Doxorubicin—urinary bladder cancer	7.87e-05	0.000368	CcSEcCtD
Ketorolac—Vertigo—Methotrexate—urinary bladder cancer	7.87e-05	0.000368	CcSEcCtD
Ketorolac—Mediastinal disorder—Doxorubicin—urinary bladder cancer	7.85e-05	0.000367	CcSEcCtD
Ketorolac—Leukopenia—Methotrexate—urinary bladder cancer	7.84e-05	0.000367	CcSEcCtD
Ketorolac—Chills—Doxorubicin—urinary bladder cancer	7.82e-05	0.000366	CcSEcCtD
Ketorolac—Arrhythmia—Doxorubicin—urinary bladder cancer	7.78e-05	0.000364	CcSEcCtD
Ketorolac—Nausea—Cisplatin—urinary bladder cancer	7.74e-05	0.000362	CcSEcCtD
Ketorolac—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	7.73e-05	0.00291	CbGpPWpGaD
Ketorolac—Vision blurred—Epirubicin—urinary bladder cancer	7.73e-05	0.000361	CcSEcCtD
Ketorolac—Alopecia—Doxorubicin—urinary bladder cancer	7.7e-05	0.00036	CcSEcCtD
Ketorolac—Cough—Methotrexate—urinary bladder cancer	7.64e-05	0.000358	CcSEcCtD
Ketorolac—Mental disorder—Doxorubicin—urinary bladder cancer	7.63e-05	0.000357	CcSEcCtD
Ketorolac—Ill-defined disorder—Epirubicin—urinary bladder cancer	7.61e-05	0.000356	CcSEcCtD
Ketorolac—Convulsion—Methotrexate—urinary bladder cancer	7.59e-05	0.000355	CcSEcCtD
Ketorolac—Vomiting—Etoposide—urinary bladder cancer	7.59e-05	0.000355	CcSEcCtD
Ketorolac—Erythema—Doxorubicin—urinary bladder cancer	7.58e-05	0.000355	CcSEcCtD
Ketorolac—Malnutrition—Doxorubicin—urinary bladder cancer	7.58e-05	0.000355	CcSEcCtD
Ketorolac—Anaemia—Epirubicin—urinary bladder cancer	7.58e-05	0.000354	CcSEcCtD
Ketorolac—Agitation—Epirubicin—urinary bladder cancer	7.53e-05	0.000352	CcSEcCtD
Ketorolac—Rash—Etoposide—urinary bladder cancer	7.53e-05	0.000352	CcSEcCtD
Ketorolac—Dermatitis—Etoposide—urinary bladder cancer	7.52e-05	0.000352	CcSEcCtD
Ketorolac—Headache—Etoposide—urinary bladder cancer	7.48e-05	0.00035	CcSEcCtD
Ketorolac—Flatulence—Doxorubicin—urinary bladder cancer	7.47e-05	0.00035	CcSEcCtD
Ketorolac—Myalgia—Methotrexate—urinary bladder cancer	7.46e-05	0.000349	CcSEcCtD
Ketorolac—Arthralgia—Methotrexate—urinary bladder cancer	7.46e-05	0.000349	CcSEcCtD
Ketorolac—Chest pain—Methotrexate—urinary bladder cancer	7.46e-05	0.000349	CcSEcCtD
Ketorolac—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	7.44e-05	0.0028	CbGpPWpGaD
Ketorolac—Tension—Doxorubicin—urinary bladder cancer	7.44e-05	0.000348	CcSEcCtD
Ketorolac—Dysgeusia—Doxorubicin—urinary bladder cancer	7.43e-05	0.000347	CcSEcCtD
Ketorolac—PTGS1—Metabolism—GSTZ1—urinary bladder cancer	7.42e-05	0.0028	CbGpPWpGaD
Ketorolac—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	7.41e-05	0.000346	CcSEcCtD
Ketorolac—Malaise—Epirubicin—urinary bladder cancer	7.39e-05	0.000346	CcSEcCtD
Ketorolac—Discomfort—Methotrexate—urinary bladder cancer	7.37e-05	0.000345	CcSEcCtD
Ketorolac—Nervousness—Doxorubicin—urinary bladder cancer	7.37e-05	0.000345	CcSEcCtD
Ketorolac—Vertigo—Epirubicin—urinary bladder cancer	7.36e-05	0.000345	CcSEcCtD
Ketorolac—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	7.35e-05	0.00277	CbGpPWpGaD
Ketorolac—Syncope—Epirubicin—urinary bladder cancer	7.35e-05	0.000344	CcSEcCtD
Ketorolac—Leukopenia—Epirubicin—urinary bladder cancer	7.34e-05	0.000343	CcSEcCtD
Ketorolac—Back pain—Doxorubicin—urinary bladder cancer	7.34e-05	0.000343	CcSEcCtD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	7.29e-05	0.00275	CbGpPWpGaD
Ketorolac—PTGS1—Selenium Micronutrient Network—TNF—urinary bladder cancer	7.25e-05	0.00273	CbGpPWpGaD
Ketorolac—Palpitations—Epirubicin—urinary bladder cancer	7.24e-05	0.000339	CcSEcCtD
Ketorolac—Confusional state—Methotrexate—urinary bladder cancer	7.21e-05	0.000337	CcSEcCtD
Ketorolac—Loss of consciousness—Epirubicin—urinary bladder cancer	7.2e-05	0.000337	CcSEcCtD
Ketorolac—Cough—Epirubicin—urinary bladder cancer	7.15e-05	0.000335	CcSEcCtD
Ketorolac—Anaphylactic shock—Methotrexate—urinary bladder cancer	7.15e-05	0.000334	CcSEcCtD
Ketorolac—Vision blurred—Doxorubicin—urinary bladder cancer	7.15e-05	0.000334	CcSEcCtD
Ketorolac—Convulsion—Epirubicin—urinary bladder cancer	7.1e-05	0.000332	CcSEcCtD
Ketorolac—Infection—Methotrexate—urinary bladder cancer	7.1e-05	0.000332	CcSEcCtD
Ketorolac—Nausea—Etoposide—urinary bladder cancer	7.09e-05	0.000332	CcSEcCtD
Ketorolac—Hypertension—Epirubicin—urinary bladder cancer	7.08e-05	0.000331	CcSEcCtD
Ketorolac—PTGS1—Metabolism—GSTO2—urinary bladder cancer	7.04e-05	0.00265	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—NAT1—urinary bladder cancer	7.04e-05	0.00265	CbGpPWpGaD
Ketorolac—Ill-defined disorder—Doxorubicin—urinary bladder cancer	7.04e-05	0.000329	CcSEcCtD
Ketorolac—Nervous system disorder—Methotrexate—urinary bladder cancer	7.01e-05	0.000328	CcSEcCtD
Ketorolac—Anaemia—Doxorubicin—urinary bladder cancer	7.01e-05	0.000328	CcSEcCtD
Ketorolac—Thrombocytopenia—Methotrexate—urinary bladder cancer	7e-05	0.000327	CcSEcCtD
Ketorolac—Myalgia—Epirubicin—urinary bladder cancer	6.98e-05	0.000326	CcSEcCtD
Ketorolac—Arthralgia—Epirubicin—urinary bladder cancer	6.98e-05	0.000326	CcSEcCtD
Ketorolac—Chest pain—Epirubicin—urinary bladder cancer	6.98e-05	0.000326	CcSEcCtD
Ketorolac—Agitation—Doxorubicin—urinary bladder cancer	6.97e-05	0.000326	CcSEcCtD
Ketorolac—Anxiety—Epirubicin—urinary bladder cancer	6.95e-05	0.000325	CcSEcCtD
Ketorolac—Skin disorder—Methotrexate—urinary bladder cancer	6.94e-05	0.000325	CcSEcCtD
Ketorolac—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	6.93e-05	0.000324	CcSEcCtD
Ketorolac—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.92e-05	0.00261	CbGpPWpGaD
Ketorolac—Hyperhidrosis—Methotrexate—urinary bladder cancer	6.91e-05	0.000323	CcSEcCtD
Ketorolac—Discomfort—Epirubicin—urinary bladder cancer	6.9e-05	0.000323	CcSEcCtD
Ketorolac—Malaise—Doxorubicin—urinary bladder cancer	6.84e-05	0.00032	CcSEcCtD
Ketorolac—Dry mouth—Epirubicin—urinary bladder cancer	6.83e-05	0.000319	CcSEcCtD
Ketorolac—Vertigo—Doxorubicin—urinary bladder cancer	6.81e-05	0.000319	CcSEcCtD
Ketorolac—Anorexia—Methotrexate—urinary bladder cancer	6.81e-05	0.000319	CcSEcCtD
Ketorolac—Syncope—Doxorubicin—urinary bladder cancer	6.8e-05	0.000318	CcSEcCtD
Ketorolac—Leukopenia—Doxorubicin—urinary bladder cancer	6.79e-05	0.000318	CcSEcCtD
Ketorolac—Confusional state—Epirubicin—urinary bladder cancer	6.75e-05	0.000316	CcSEcCtD
Ketorolac—PTGS1—female reproductive system—urinary bladder cancer	6.74e-05	0.0493	CbGeAlD
Ketorolac—Palpitations—Doxorubicin—urinary bladder cancer	6.7e-05	0.000314	CcSEcCtD
Ketorolac—Oedema—Epirubicin—urinary bladder cancer	6.69e-05	0.000313	CcSEcCtD
Ketorolac—Anaphylactic shock—Epirubicin—urinary bladder cancer	6.69e-05	0.000313	CcSEcCtD
Ketorolac—Hypotension—Methotrexate—urinary bladder cancer	6.68e-05	0.000312	CcSEcCtD
Ketorolac—PTGS2—Disease—GSTO2—urinary bladder cancer	6.67e-05	0.00251	CbGpPWpGaD
Ketorolac—Loss of consciousness—Doxorubicin—urinary bladder cancer	6.67e-05	0.000312	CcSEcCtD
Ketorolac—Infection—Epirubicin—urinary bladder cancer	6.65e-05	0.000311	CcSEcCtD
Ketorolac—Cough—Doxorubicin—urinary bladder cancer	6.62e-05	0.00031	CcSEcCtD
Ketorolac—Shock—Epirubicin—urinary bladder cancer	6.58e-05	0.000308	CcSEcCtD
Ketorolac—Convulsion—Doxorubicin—urinary bladder cancer	6.57e-05	0.000307	CcSEcCtD
Ketorolac—Nervous system disorder—Epirubicin—urinary bladder cancer	6.56e-05	0.000307	CcSEcCtD
Ketorolac—Thrombocytopenia—Epirubicin—urinary bladder cancer	6.55e-05	0.000306	CcSEcCtD
Ketorolac—Hypertension—Doxorubicin—urinary bladder cancer	6.55e-05	0.000306	CcSEcCtD
Ketorolac—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	6.53e-05	0.00246	CbGpPWpGaD
Ketorolac—Tachycardia—Epirubicin—urinary bladder cancer	6.53e-05	0.000305	CcSEcCtD
Ketorolac—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	6.51e-05	0.000305	CcSEcCtD
Ketorolac—Skin disorder—Epirubicin—urinary bladder cancer	6.5e-05	0.000304	CcSEcCtD
Ketorolac—Hyperhidrosis—Epirubicin—urinary bladder cancer	6.47e-05	0.000303	CcSEcCtD
Ketorolac—Insomnia—Methotrexate—urinary bladder cancer	6.47e-05	0.000302	CcSEcCtD
Ketorolac—Chest pain—Doxorubicin—urinary bladder cancer	6.46e-05	0.000302	CcSEcCtD
Ketorolac—Arthralgia—Doxorubicin—urinary bladder cancer	6.46e-05	0.000302	CcSEcCtD
Ketorolac—Myalgia—Doxorubicin—urinary bladder cancer	6.46e-05	0.000302	CcSEcCtD
Ketorolac—PTGS2—female reproductive system—urinary bladder cancer	6.44e-05	0.0472	CbGeAlD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	6.44e-05	0.00243	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—UGT2B7—urinary bladder cancer	6.44e-05	0.00243	CbGpPWpGaD
Ketorolac—Anxiety—Doxorubicin—urinary bladder cancer	6.43e-05	0.000301	CcSEcCtD
Ketorolac—Paraesthesia—Methotrexate—urinary bladder cancer	6.42e-05	0.0003	CcSEcCtD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	6.41e-05	0.00242	CbGpPWpGaD
Ketorolac—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	6.41e-05	0.0003	CcSEcCtD
Ketorolac—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	6.41e-05	0.00241	CbGpPWpGaD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	6.39e-05	0.00241	CbGpPWpGaD
Ketorolac—Discomfort—Doxorubicin—urinary bladder cancer	6.38e-05	0.000298	CcSEcCtD
Ketorolac—Anorexia—Epirubicin—urinary bladder cancer	6.38e-05	0.000298	CcSEcCtD
Ketorolac—Dyspnoea—Methotrexate—urinary bladder cancer	6.37e-05	0.000298	CcSEcCtD
Ketorolac—Somnolence—Methotrexate—urinary bladder cancer	6.36e-05	0.000297	CcSEcCtD
Ketorolac—Dry mouth—Doxorubicin—urinary bladder cancer	6.32e-05	0.000295	CcSEcCtD
Ketorolac—Dyspepsia—Methotrexate—urinary bladder cancer	6.29e-05	0.000294	CcSEcCtD
Ketorolac—Hypotension—Epirubicin—urinary bladder cancer	6.25e-05	0.000292	CcSEcCtD
Ketorolac—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	6.25e-05	0.00235	CbGpPWpGaD
Ketorolac—Confusional state—Doxorubicin—urinary bladder cancer	6.24e-05	0.000292	CcSEcCtD
Ketorolac—Decreased appetite—Methotrexate—urinary bladder cancer	6.21e-05	0.000291	CcSEcCtD
Ketorolac—Anaphylactic shock—Doxorubicin—urinary bladder cancer	6.19e-05	0.00029	CcSEcCtD
Ketorolac—Oedema—Doxorubicin—urinary bladder cancer	6.19e-05	0.00029	CcSEcCtD
Ketorolac—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	6.17e-05	0.000289	CcSEcCtD
Ketorolac—Fatigue—Methotrexate—urinary bladder cancer	6.16e-05	0.000288	CcSEcCtD
Ketorolac—Infection—Doxorubicin—urinary bladder cancer	6.15e-05	0.000288	CcSEcCtD
Ketorolac—Pain—Methotrexate—urinary bladder cancer	6.11e-05	0.000286	CcSEcCtD
Ketorolac—PTGS1—vagina—urinary bladder cancer	6.1e-05	0.0446	CbGeAlD
Ketorolac—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	6.1e-05	0.000285	CcSEcCtD
Ketorolac—Shock—Doxorubicin—urinary bladder cancer	6.09e-05	0.000285	CcSEcCtD
Ketorolac—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	6.09e-05	0.00229	CbGpPWpGaD
Ketorolac—Nervous system disorder—Doxorubicin—urinary bladder cancer	6.07e-05	0.000284	CcSEcCtD
Ketorolac—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.06e-05	0.000284	CcSEcCtD
Ketorolac—Insomnia—Epirubicin—urinary bladder cancer	6.05e-05	0.000283	CcSEcCtD
Ketorolac—Tachycardia—Doxorubicin—urinary bladder cancer	6.04e-05	0.000283	CcSEcCtD
Ketorolac—Skin disorder—Doxorubicin—urinary bladder cancer	6.01e-05	0.000281	CcSEcCtD
Ketorolac—Paraesthesia—Epirubicin—urinary bladder cancer	6.01e-05	0.000281	CcSEcCtD
Ketorolac—Hyperhidrosis—Doxorubicin—urinary bladder cancer	5.98e-05	0.00028	CcSEcCtD
Ketorolac—Dyspnoea—Epirubicin—urinary bladder cancer	5.96e-05	0.000279	CcSEcCtD
Ketorolac—Somnolence—Epirubicin—urinary bladder cancer	5.95e-05	0.000278	CcSEcCtD
Ketorolac—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	5.92e-05	0.00223	CbGpPWpGaD
Ketorolac—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	5.91e-05	0.00223	CbGpPWpGaD
Ketorolac—Anorexia—Doxorubicin—urinary bladder cancer	5.9e-05	0.000276	CcSEcCtD
Ketorolac—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	5.89e-05	0.00222	CbGpPWpGaD
Ketorolac—Feeling abnormal—Methotrexate—urinary bladder cancer	5.89e-05	0.000276	CcSEcCtD
Ketorolac—Dyspepsia—Epirubicin—urinary bladder cancer	5.89e-05	0.000275	CcSEcCtD
Ketorolac—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5.85e-05	0.000273	CcSEcCtD
Ketorolac—PTGS2—vagina—urinary bladder cancer	5.83e-05	0.0427	CbGeAlD
Ketorolac—Decreased appetite—Epirubicin—urinary bladder cancer	5.82e-05	0.000272	CcSEcCtD
Ketorolac—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	5.8e-05	0.00218	CbGpPWpGaD
Ketorolac—Hypotension—Doxorubicin—urinary bladder cancer	5.78e-05	0.000271	CcSEcCtD
Ketorolac—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	5.78e-05	0.00027	CcSEcCtD
Ketorolac—Fatigue—Epirubicin—urinary bladder cancer	5.77e-05	0.00027	CcSEcCtD
Ketorolac—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	5.75e-05	0.00217	CbGpPWpGaD
Ketorolac—Pain—Epirubicin—urinary bladder cancer	5.72e-05	0.000268	CcSEcCtD
Ketorolac—Constipation—Epirubicin—urinary bladder cancer	5.72e-05	0.000268	CcSEcCtD
Ketorolac—Urticaria—Methotrexate—urinary bladder cancer	5.68e-05	0.000266	CcSEcCtD
Ketorolac—Body temperature increased—Methotrexate—urinary bladder cancer	5.65e-05	0.000264	CcSEcCtD
Ketorolac—Abdominal pain—Methotrexate—urinary bladder cancer	5.65e-05	0.000264	CcSEcCtD
Ketorolac—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.64e-05	0.000264	CcSEcCtD
Ketorolac—Insomnia—Doxorubicin—urinary bladder cancer	5.6e-05	0.000262	CcSEcCtD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	5.6e-05	0.00211	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—GSTO2—urinary bladder cancer	5.59e-05	0.00211	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—NAT1—urinary bladder cancer	5.59e-05	0.00211	CbGpPWpGaD
Ketorolac—Paraesthesia—Doxorubicin—urinary bladder cancer	5.56e-05	0.00026	CcSEcCtD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	5.53e-05	0.00208	CbGpPWpGaD
Ketorolac—Dyspnoea—Doxorubicin—urinary bladder cancer	5.52e-05	0.000258	CcSEcCtD
Ketorolac—Feeling abnormal—Epirubicin—urinary bladder cancer	5.51e-05	0.000258	CcSEcCtD
Ketorolac—Somnolence—Doxorubicin—urinary bladder cancer	5.5e-05	0.000257	CcSEcCtD
Ketorolac—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.5e-05	0.00207	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	5.47e-05	0.00206	CbGpPWpGaD
Ketorolac—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.47e-05	0.000256	CcSEcCtD
Ketorolac—Dyspepsia—Doxorubicin—urinary bladder cancer	5.45e-05	0.000255	CcSEcCtD
Ketorolac—Decreased appetite—Doxorubicin—urinary bladder cancer	5.38e-05	0.000252	CcSEcCtD
Ketorolac—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	5.34e-05	0.00025	CcSEcCtD
Ketorolac—Fatigue—Doxorubicin—urinary bladder cancer	5.34e-05	0.00025	CcSEcCtD
Ketorolac—PTGS1—Metabolism—PRSS3—urinary bladder cancer	5.33e-05	0.00201	CbGpPWpGaD
Ketorolac—Urticaria—Epirubicin—urinary bladder cancer	5.31e-05	0.000249	CcSEcCtD
Ketorolac—Pain—Doxorubicin—urinary bladder cancer	5.29e-05	0.000248	CcSEcCtD
Ketorolac—Constipation—Doxorubicin—urinary bladder cancer	5.29e-05	0.000248	CcSEcCtD
Ketorolac—Body temperature increased—Epirubicin—urinary bladder cancer	5.29e-05	0.000247	CcSEcCtD
Ketorolac—Abdominal pain—Epirubicin—urinary bladder cancer	5.29e-05	0.000247	CcSEcCtD
Ketorolac—Hypersensitivity—Methotrexate—urinary bladder cancer	5.27e-05	0.000246	CcSEcCtD
Ketorolac—PTGS2—Disease—SLC19A1—urinary bladder cancer	5.19e-05	0.00195	CbGpPWpGaD
Ketorolac—Asthenia—Methotrexate—urinary bladder cancer	5.13e-05	0.00024	CcSEcCtD
Ketorolac—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	5.11e-05	0.00193	CbGpPWpGaD
Ketorolac—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.1e-05	0.000239	CcSEcCtD
Ketorolac—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.06e-05	0.000237	CcSEcCtD
Ketorolac—Pruritus—Methotrexate—urinary bladder cancer	5.06e-05	0.000237	CcSEcCtD
Ketorolac—PTGS2—Disease—PRSS3—urinary bladder cancer	5.06e-05	0.00191	CbGpPWpGaD
Ketorolac—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	5.03e-05	0.0019	CbGpPWpGaD
Ketorolac—Hypersensitivity—Epirubicin—urinary bladder cancer	4.93e-05	0.000231	CcSEcCtD
Ketorolac—Urticaria—Doxorubicin—urinary bladder cancer	4.92e-05	0.00023	CcSEcCtD
Ketorolac—Body temperature increased—Doxorubicin—urinary bladder cancer	4.89e-05	0.000229	CcSEcCtD
Ketorolac—Abdominal pain—Doxorubicin—urinary bladder cancer	4.89e-05	0.000229	CcSEcCtD
Ketorolac—Diarrhoea—Methotrexate—urinary bladder cancer	4.89e-05	0.000229	CcSEcCtD
Ketorolac—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	4.88e-05	0.00184	CbGpPWpGaD
Ketorolac—PTGS2—Disease—HDAC4—urinary bladder cancer	4.82e-05	0.00182	CbGpPWpGaD
Ketorolac—Asthenia—Epirubicin—urinary bladder cancer	4.8e-05	0.000225	CcSEcCtD
Ketorolac—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	4.78e-05	0.0018	CbGpPWpGaD
Ketorolac—Pruritus—Epirubicin—urinary bladder cancer	4.73e-05	0.000221	CcSEcCtD
Ketorolac—Dizziness—Methotrexate—urinary bladder cancer	4.73e-05	0.000221	CcSEcCtD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	4.69e-05	0.00177	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	4.6e-05	0.00173	CbGpPWpGaD
Ketorolac—Diarrhoea—Epirubicin—urinary bladder cancer	4.58e-05	0.000214	CcSEcCtD
Ketorolac—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.56e-05	0.000213	CcSEcCtD
Ketorolac—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	4.55e-05	0.00171	CbGpPWpGaD
Ketorolac—Vomiting—Methotrexate—urinary bladder cancer	4.55e-05	0.000213	CcSEcCtD
Ketorolac—Rash—Methotrexate—urinary bladder cancer	4.51e-05	0.000211	CcSEcCtD
Ketorolac—Dermatitis—Methotrexate—urinary bladder cancer	4.5e-05	0.000211	CcSEcCtD
Ketorolac—Headache—Methotrexate—urinary bladder cancer	4.48e-05	0.000209	CcSEcCtD
Ketorolac—Asthenia—Doxorubicin—urinary bladder cancer	4.44e-05	0.000208	CcSEcCtD
Ketorolac—Dizziness—Epirubicin—urinary bladder cancer	4.42e-05	0.000207	CcSEcCtD
Ketorolac—Pruritus—Doxorubicin—urinary bladder cancer	4.38e-05	0.000205	CcSEcCtD
Ketorolac—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	4.35e-05	0.00164	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.28e-05	0.00161	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—TYMP—urinary bladder cancer	4.26e-05	0.00161	CbGpPWpGaD
Ketorolac—Vomiting—Epirubicin—urinary bladder cancer	4.25e-05	0.000199	CcSEcCtD
Ketorolac—Nausea—Methotrexate—urinary bladder cancer	4.25e-05	0.000199	CcSEcCtD
Ketorolac—Diarrhoea—Doxorubicin—urinary bladder cancer	4.24e-05	0.000198	CcSEcCtD
Ketorolac—PTGS2—Metabolism—PRSS3—urinary bladder cancer	4.23e-05	0.0016	CbGpPWpGaD
Ketorolac—Rash—Epirubicin—urinary bladder cancer	4.22e-05	0.000197	CcSEcCtD
Ketorolac—Dermatitis—Epirubicin—urinary bladder cancer	4.21e-05	0.000197	CcSEcCtD
Ketorolac—Headache—Epirubicin—urinary bladder cancer	4.19e-05	0.000196	CcSEcCtD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.14e-05	0.00156	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.1e-05	0.00154	CbGpPWpGaD
Ketorolac—Dizziness—Doxorubicin—urinary bladder cancer	4.09e-05	0.000191	CcSEcCtD
Ketorolac—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	4.01e-05	0.00151	CbGpPWpGaD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.01e-05	0.00151	CbGpPWpGaD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4e-05	0.00151	CbGpPWpGaD
Ketorolac—Nausea—Epirubicin—urinary bladder cancer	3.97e-05	0.000186	CcSEcCtD
Ketorolac—PTGS1—lymph node—urinary bladder cancer	3.94e-05	0.0289	CbGeAlD
Ketorolac—Vomiting—Doxorubicin—urinary bladder cancer	3.94e-05	0.000184	CcSEcCtD
Ketorolac—Rash—Doxorubicin—urinary bladder cancer	3.9e-05	0.000183	CcSEcCtD
Ketorolac—Dermatitis—Doxorubicin—urinary bladder cancer	3.9e-05	0.000182	CcSEcCtD
Ketorolac—Headache—Doxorubicin—urinary bladder cancer	3.88e-05	0.000181	CcSEcCtD
Ketorolac—PTGS1—Metabolism—NAT2—urinary bladder cancer	3.86e-05	0.00145	CbGpPWpGaD
Ketorolac—PTGS2—Disease—LIG1—urinary bladder cancer	3.83e-05	0.00144	CbGpPWpGaD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.81e-05	0.00144	CbGpPWpGaD
Ketorolac—PTGS2—lymph node—urinary bladder cancer	3.77e-05	0.0276	CbGeAlD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.71e-05	0.0014	CbGpPWpGaD
Ketorolac—Nausea—Doxorubicin—urinary bladder cancer	3.68e-05	0.000172	CcSEcCtD
Ketorolac—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.4e-05	0.00128	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—TYMP—urinary bladder cancer	3.39e-05	0.00128	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—RRM2—urinary bladder cancer	3.33e-05	0.00125	CbGpPWpGaD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.32e-05	0.00125	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.25e-05	0.00123	CbGpPWpGaD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.25e-05	0.00122	CbGpPWpGaD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.09e-05	0.00117	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—HPGDS—urinary bladder cancer	3.08e-05	0.00116	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—ENO2—urinary bladder cancer	3.08e-05	0.00116	CbGpPWpGaD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.07e-05	0.00116	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.06e-05	0.00115	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—NAT2—urinary bladder cancer	3.06e-05	0.00115	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—GSTT1—urinary bladder cancer	2.99e-05	0.00113	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.94e-05	0.00111	CbGpPWpGaD
Ketorolac—PTGS2—Disease—ENO2—urinary bladder cancer	2.92e-05	0.0011	CbGpPWpGaD
Ketorolac—PTGS2—Disease—RBX1—urinary bladder cancer	2.77e-05	0.00104	CbGpPWpGaD
Ketorolac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.73e-05	0.00103	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—RRM2—urinary bladder cancer	2.64e-05	0.000996	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—NQO1—urinary bladder cancer	2.48e-05	0.000936	CbGpPWpGaD
Ketorolac—PTGS2—Disease—JAG1—urinary bladder cancer	2.48e-05	0.000934	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—HPGDS—urinary bladder cancer	2.45e-05	0.000922	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—ENO2—urinary bladder cancer	2.45e-05	0.000922	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.43e-05	0.000917	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.41e-05	0.000908	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—GSTT1—urinary bladder cancer	2.37e-05	0.000894	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.34e-05	0.000881	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.1e-05	0.000792	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—GSTP1—urinary bladder cancer	2.07e-05	0.000781	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.01e-05	0.000756	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.97e-05	0.000743	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—TYMS—urinary bladder cancer	1.93e-05	0.000726	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—NCOR1—urinary bladder cancer	1.9e-05	0.000718	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—GSTM1—urinary bladder cancer	1.9e-05	0.000718	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—GPX1—urinary bladder cancer	1.82e-05	0.000687	CbGpPWpGaD
Ketorolac—PTGS2—Disease—NCOR1—urinary bladder cancer	1.81e-05	0.00068	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—ERCC2—urinary bladder cancer	1.79e-05	0.000675	CbGpPWpGaD
Ketorolac—PTGS2—Disease—ERCC2—urinary bladder cancer	1.7e-05	0.00064	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.68e-05	0.000634	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.67e-05	0.000629	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.65e-05	0.00062	CbGpPWpGaD
Ketorolac—PTGS2—Disease—MTHFR—urinary bladder cancer	1.6e-05	0.000601	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.59e-05	0.0006	CbGpPWpGaD
Ketorolac—PTGS2—Disease—TERT—urinary bladder cancer	1.59e-05	0.0006	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.53e-05	0.000576	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.51e-05	0.00057	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.51e-05	0.00057	CbGpPWpGaD
Ketorolac—PTGS2—Disease—FGFR3—urinary bladder cancer	1.46e-05	0.00055	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.45e-05	0.000546	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.42e-05	0.000536	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.36e-05	0.000514	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.34e-05	0.000504	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.31e-05	0.000494	CbGpPWpGaD
Ketorolac—PTGS2—Disease—CREBBP—urinary bladder cancer	1.24e-05	0.000468	CbGpPWpGaD
Ketorolac—PTGS2—Disease—RHOA—urinary bladder cancer	1.12e-05	0.000424	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—PPARG—urinary bladder cancer	1.08e-05	0.000408	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—PTGS2—urinary bladder cancer	1.07e-05	0.000405	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—CREBBP—urinary bladder cancer	1.04e-05	0.000392	CbGpPWpGaD
Ketorolac—PTGS2—Disease—ERBB2—urinary bladder cancer	1.04e-05	0.000392	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—PTEN—urinary bladder cancer	9.36e-06	0.000353	CbGpPWpGaD
Ketorolac—PTGS1—Metabolism—EP300—urinary bladder cancer	8.93e-06	0.000336	CbGpPWpGaD
Ketorolac—PTGS2—Disease—CDKN1A—urinary bladder cancer	8.9e-06	0.000335	CbGpPWpGaD
Ketorolac—PTGS2—Disease—PTEN—urinary bladder cancer	8.88e-06	0.000334	CbGpPWpGaD
Ketorolac—PTGS2—Disease—EP300—urinary bladder cancer	8.47e-06	0.000319	CbGpPWpGaD
Ketorolac—PTGS2—Disease—SRC—urinary bladder cancer	8.23e-06	0.00031	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—PTEN—urinary bladder cancer	7.43e-06	0.00028	CbGpPWpGaD
Ketorolac—PTGS2—Disease—MYC—urinary bladder cancer	7.38e-06	0.000278	CbGpPWpGaD
Ketorolac—PTGS2—Disease—EGFR—urinary bladder cancer	7.21e-06	0.000272	CbGpPWpGaD
Ketorolac—PTGS2—Metabolism—EP300—urinary bladder cancer	7.09e-06	0.000267	CbGpPWpGaD
Ketorolac—PTGS2—Disease—KRAS—urinary bladder cancer	6.82e-06	0.000257	CbGpPWpGaD
Ketorolac—PTGS2—Disease—HRAS—urinary bladder cancer	5.79e-06	0.000218	CbGpPWpGaD
